SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The filing discloses the closing of an acquisition of ThermoKey S.p.A. by Vertiv's wholly-owned subsidiary. This is a material acquisition event that would affect a reasonable investor's assessment of the company's strategic direction and financial position. The disclosure of the acquisition closing is the principal event, even though it is furnished under Item 7.01 (Regulation FD) rather than the more typical Item 1.01 or 2.01.
View raw filing on EDGAR →HPS Corporate Lending Fund discloses a letter regarding its second quarter 2026 tender offer under Regulation FD. While tender offers can be material to shareholders (affecting liquidity and valuation), this disclosure is limited to furnishing a letter without substantive detail in the 8-K itself. The event does not fit neatly into standard categories (not M&A, not exec-related, not financial restatement), making "other_material" the most appropriate classification, though the materiality assessment reflects uncertainty about the tender offer's significance without seeing the full letter.
View raw filing on EDGAR →The Fund discloses preliminary results of a tender offer for approximately 4.7% of outstanding common shares (2,280,500 shares) that expired June 8, 2026, with purchase price based on NAV as of June 30, 2026. While share repurchases are routine for closed-end funds, a tender offer affecting nearly 5% of shares is a material capital allocation event that would affect investor assessment of the Fund's capital structure and share count. This does not fit neatly into the specific taxonomy categories (not M&A, not dilutive issuance, not a routine administrative matter), warranting classification as other_material.
View raw filing on EDGAR →The filing discloses a dividend declaration on common stock and Series B Preferred Shares via press release under Item 2.02 (Results of Operations and Financial Condition). While dividend declarations are material corporate actions affecting shareholder value, this disclosure does not fit the earnings_release category (which typically reports quarterly/annual financial results) nor any other specific event type. The material nature of dividend declarations to investors warrants classification as other_material rather than a routine administrative disclosure.
View raw filing on EDGAR →This exhibit is a formal Report of Voting Results filed pursuant to National Instrument 51-102 Section 11.3, disclosing the results of Aya Gold & Silver Inc.'s annual shareholders' meeting held on June 12, 2026. It tabulates voting outcomes for three resolutions: election of eight directors, appointment of KPMG LLP as auditors, and an advisory vote on executive compensation. The document explicitly states it is furnished "in accordance with section 11.3 of NI 51-102," confirming it is a mandatory shareholder-vote-results disclosure.
View raw filing on EDGAR →This press release discloses the results of Aya Gold & Silver's annual general meeting of shareholders held on June 12, 2026. It reports detailed voting results for the election of eight director nominees (all approved), the appointment of KPMG LLP as auditors, and an advisory vote on executive compensation. The disclosure includes vote counts and percentages for each director and resolution, which is the core content required for shareholder_vote_results classification.
View raw filing on EDGAR →This disclosure reports the monthly NAV per share for Rithm Perpetual Life Residential Trust as of May 31, 2026, broken down by share class (Class J at $20.1602 and Class E at $20.2647) with detailed asset and liability components. While NAV reporting is routine for closed-end funds and trusts, the disclosure of current NAV per share is material to investors in assessing the fund's value and performance. However, this does not fit neatly into the more specific event categories (it is not an earnings release, impairment, restatement, or other discrete corporate action), making "other_material" the most appropriate classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the June 10, 2026 Annual Meeting of Stockholders, including election of two Class II directors, ratification of auditors, approval of convertible note issuance and warrant conversion rights, and adjournment authority. The filing directly reports voting outcomes with vote counts for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →Shareholders voted at the June 11, 2026 annual meeting on three matters: election of two Class I directors (Victor K. Lee and Jeff Zhou), ratification of Ernst & Young LLP as independent auditor, and advisory approval of 2025 named executive officer compensation. Detailed voting tallies including for, against, withheld, abstentions, and broker non-votes were disclosed.
View raw filing on EDGAR →The company announced a quarterly cash dividend of $2.00 per share, representing a material capital allocation decision affecting shareholder returns.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Fortrea Holdings' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing reports voting outcomes on three proposals: election of directors (Anshul Thakral, Peter M. Neupert, and William J. Sharbaugh), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Withheld, Abstained, Broker Non-Votes) are characteristic of Item 5.07 disclosures and are material to investors assessing board composition and governance outcomes.
View raw filing on EDGAR →Forbright completed its initial public offering on June 11, 2026, issuing 7.9 million shares at $18.00 per share for approximately $142.2 million in gross proceeds, and simultaneously amended and restated its certificate of incorporation and bylaws to establish the capital structure and governance framework for the newly public company.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from ACM Research's 2026 Annual Meeting held on June 10, 2026. The filing reports voting outcomes for two proposals: election of four directors (David H. Wang, Haiping Dun, Tracy Liu, and Charles Pappis) and ratification of Ernst & Young Hua Ming LLP as independent auditor for 2026. All four director nominees were elected and the auditor appointment was ratified by substantial majorities, making this a routine but material governance disclosure required under Item 5.07.
View raw filing on EDGAR →Camp4 held its Annual Meeting of Stockholders on June 10, 2026, with shareholders voting on three proposals: election of three Class II directors (Steven Holtzman, Murray Stewart, and Richard Young), ratification of Ernst & Young LLP as independent auditor, and approval of an amendment to the 2024 Equity Incentive Plan to modify the evergreen provision to include pre-funded warrants in the share calculation. All three proposals passed with detailed vote tallies disclosed.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Comcast's June 10, 2026 annual meeting, covering four proposals: director elections, auditor ratification, advisory compensation vote, and an independent chair proposal. Item 5.07 explicitly requires disclosure of shareholder vote results, and the detailed vote tallies for each proposal constitute material information affecting investor assessment of corporate governance and management accountability.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from GPGI's 2026 Annual Meeting held on June 11, 2026. The filing reports voting outcomes on four proposals: election of four Class II directors, advisory Say-on-Pay approval, Say-on-Frequency determination (annual voting approved), and auditor ratification. All proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely upon to assess board composition and executive compensation oversight.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Hagerty's 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting outcomes for four proposals: election of nine directors (all receiving majority affirmative votes), advisory approval of named executive officer compensation, advisory frequency vote on compensation (one year recommended), and ratification of Deloitte & Touche LLP as independent auditor. The detailed vote tallies and broker non-votes are characteristic of shareholder vote result disclosures required under Item 5.07.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Asana's June 8, 2026 Annual Meeting of Stockholders, covering three proposals: election of three Class III directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents the final vote tallies for each proposal, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Ginkgo Bioworks' 2026 annual meeting of shareholders held on June 11, 2026. The filing presents detailed voting results for three proposals: election of six directors (with separate voting by Class A and Class B shareholders), ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on executive compensation. All three proposals passed with substantial majorities. Shareholder vote results are material to investors as they determine board composition and affirm key governance decisions.
View raw filing on EDGAR →Caro Holdings entered into an Asset Purchase and Acquisition Agreement to acquire a 49% interest in mining properties in Tanzania, funded through the issuance of 20,000,000 shares of common stock to Goldrange.
View raw filing on EDGAR →This press release announces Phase III clinical trial results for sovleplenib (ESLIM-02 study) in warm antibody autoimmune hemolytic anemia, presented at EHA 2026 Congress. The disclosure highlights that the study met its primary endpoint with statistically significant efficacy data (66% durable response vs 15% placebo, p<0.0001) and a favorable safety profile. While this is a clinical milestone rather than financial results, it represents a material operational and regulatory event: the NMPA has accepted the NDA for priority review and granted Breakthrough Therapy Designation, positioning sovleplenib as a potential commercial product addressing an unmet medical need in a treatment-sparse landscape. The data directly supports regulatory advancement and future revenue potential.
View raw filing on EDGAR →GSK announced that momelotinib received Orphan Drug Designations (ODD) from the FDA and EMA for VEXAS syndrome treatment, with a planned phase II/III ATLAS trial underway. This is a material regulatory milestone for a rare disease indication that would affect investor assessment of the company's pipeline and development strategy, but it does not fit the specific event categories (not an earnings release, M&A activity, executive change, debt issuance, or other named types). The ODD designation and trial advancement represent a significant operational/strategic development in the drug's regulatory pathway.
View raw filing on EDGAR →Noble Romans entered into a material senior secured term loan agreement with Lake Forest Bank & Trust Company on June 10, 2026, for $6.9 million, and simultaneously terminated a prior material definitive agreement. The loan proceeds were used to refinance existing debt obligations, redeem warrants, and pay advisory fees, materially restructuring the company's capital structure and debt obligations.
View raw filing on EDGAR →This exhibit discloses the results of the Company's Annual General Meeting held on June 9, 2026, with detailed voting outcomes on four resolutions: cancellation of Ms. Jannu Binti Babjan's directorship, appointment of Mr. Uwe Henke von Parpart as director, approval of an Employee Stock Option Plan, and consolidation of capital. All resolutions were approved by greater than 50% of shareholders present by polls, making this a clear shareholder_vote_results disclosure.
View raw filing on EDGAR →HF Foods adopted a shareholder rights plan (poison pill) on June 12, 2026, with one Right per share exercisable at $9.55 per one one-thousandth of a share of Series AA Participating Preferred Stock. The plan is triggered by any person or group acquiring 15% or more of Common Stock without Board approval and is designed to deter hostile takeovers by imposing a significant penalty on such acquirers.
View raw filing on EDGAR →The exhibit discloses utilization of an "At the Market" (ATM) sales agreement with Cantor Fitzgerald & Co, announced December 17, 2024. Although no securities were actually issued during the reporting period (December 16, 2025 to June 12, 2026), the disclosure reports on the block admission of 4,000,000 depositary interests representing common shares available under the ATM scheme. ATM agreements represent standing authority to issue equity on a dilutive basis and are material capital-raising mechanisms, particularly for smaller issuers, even when no shares are issued in a given period.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the results of the Company's Annual Meeting of Stockholders held on June 11, 2026, reporting the election of four directors (Andrey Semechkin, Russell Kern, Donald A. Wright, and Paul V. Maier) with vote tallies showing overwhelming support. Director elections are material governance events affecting the composition of the board and thus the registrant's oversight and strategic direction.
View raw filing on EDGAR →Delta Air Lines entered into a new $2.65 billion credit facility on June 11, 2026, which refinances and replaces its existing credit agreement dated November 6, 2023. The facility includes financial covenants, an accordion feature allowing expansion to $3.65 billion, and customary events of default, constituting a material refinancing transaction affecting the company's capital structure and financial flexibility.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Praxis Precision Medicines' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing presents voting results for three proposals: election of Class III directors (Gregory Norden, Marcio Souza, and William Young), ratification of Ernst & Young LLP as independent auditor, and an advisory vote on executive compensation. All three proposals passed with substantial majorities, making this a material shareholder vote results disclosure.
View raw filing on EDGAR →The company disclosed interim responder analysis data from a Phase 3 clinical trial (CAPTIVATE) for claseprubart in CIDP via an updated corporate presentation posted to its investor relations website. While clinical trial data updates can be material to investors evaluating the company's pipeline and regulatory prospects, this disclosure does not fit neatly into the more specific event categories (e.g., it is not a formal earnings release, M&A activity, or executive change). The interim nature and presentation format suggest this is a material clinical milestone, warranting classification as other_material rather than forcing it into an ill-fitting category.
View raw filing on EDGAR →This Item 5.07 discloses the results of Optimum Communications' 2026 Annual Meeting of Stockholders held on June 10, 2026, including voting tallies for the election of nine directors (Patrick Drahi, David Drahi, Dexter Goei, Dennis Mathew, Mark Mullen, Dennis Okhuijsen, Susan Schnabel, Charles Stewart, and Raymond Svider) and ratification of KPMG LLP as independent auditor. The detailed vote counts for and against each proposal are provided, making this a clear shareholder_vote_results disclosure. Board composition and auditor ratification are material to investors' assessment of governance and financial oversight.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from AbCellera's Annual Meeting of Shareholders held on June 11, 2026. The filing reports voting outcomes for three proposals: (i) election of two Class III directors (John S. Montalbano and Stephen R. Quake), (ii) ratification of Ernst & Young LLP as independent auditor, and (iii) advisory approval of named executive officer compensation. All three proposals were approved by shareholders, with detailed vote tallies provided for each. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms board composition and auditor ratification.
View raw filing on EDGAR →Angi Inc. held its Annual Meeting of Stockholders on June 10, 2026, with shareholders voting on three proposals: election of three Class II directors (Sandra Buchanan, Thomas C. Pickett Jr., and Glenn H. Schiffman), approval of the amended and restated 2017 Stock Plan, and ratification of Ernst & Young LLP as independent auditor. All three proposals passed with disclosed vote tallies.
View raw filing on EDGAR →Stockholders voted at the Annual Meeting on four proposals: election of six directors, advisory vote on executive compensation, approval of the Third Amended and Restated Omnibus Incentive Plan (increasing share pool by 2.5 million shares and extending the plan to 2036), and ratification of Grant Thornton as independent auditor. All proposals passed.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Arcus Biosciences' June 11, 2026 annual meeting, covering three proposals: election of Class II directors (Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents detailed vote tallies (votes for, against, withheld, abstentions, and broker non-votes) for each proposal, which is the standard format for Item 5.07 disclosures and constitutes material information about corporate governance outcomes.
View raw filing on EDGAR →The disclosure centers on Amendment No. 1 to Danny Rittman's employment agreement as CTO/CISO, which modifies his compensation through: (1) a base salary increase to $180,000 effective June 1, 2026; and (2) a grant of 1,000,000 performance-based stock options at $4.98/share with milestone-based vesting tied to technical deliverables (VisionRF data room, StratumAI agent release, cybersecurity framework, and EDA strategy room). While the title update is noted, the substantive disclosure is compensatory in nature—salary adjustment and equity grant—making this an exec_compensation event rather than appointment or departure.
View raw filing on EDGAR →Sadot Group entered into a Written Option Agreement granting an exclusive, irrevocable six-month option to acquire 100% of membership interests in seven California-based real estate LLCs representing 147 residential units with a total agreed portfolio value of $125.5 million and equity value of $69.5 million.
View raw filing on EDGAR →The Company issued 132,803 shares of Common Stock (17.71% of outstanding shares) on June 6, 2026, as payment for an Option Fee under the Option Agreement, pursuant to Section 4(a)(2) of the Securities Act as an unregistered private placement to an accredited investor.
View raw filing on EDGAR →Splash Beverage Group invested $217,479.24 to acquire 2,000,000 common shares and 1,000,000 warrants of Avicanna Inc. in a private placement, representing a strategic capital allocation aligned with the Company's pivot into a cannabinoid-based platform.
View raw filing on EDGAR →Michael Bondurant was appointed as Chief Operating Officer, effective June 8, 2026. The appointment also includes compensatory arrangements for Bondurant and Brady Cobb (base salary, performance bonuses, and stock option grants) and adoption of an RSU Plan.
View raw filing on EDGAR →Jason Pernell, President of Trulieve Cannabis Corp., terminated his employment effective immediately on June 11, 2026, pursuant to a mutual agreement and Separation Agreement. The disclosure centers on the departure of a named executive officer from a senior position, with associated severance arrangements including cash payment, COBRA continuation, and equity vesting. This is a material executive departure that would affect investor assessment of the company's leadership and operational continuity.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Opendoor's 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing reports voting outcomes for three proposals: election of three Class III directors (David Benson, Eric Feder, Eric Wu), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Clover Health's June 10, 2026 Annual Meeting of Stockholders. The filing reports final voting tallies on three proposals: election of three Class II directors (Kouzoukas, Toy, and Tran), a non-binding advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. All three proposals passed with substantial majorities. Shareholder meeting outcomes are material to investors as they determine board composition and affirm key governance decisions.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from LENZ Therapeutics' 2026 annual meeting held on June 12, 2026. The filing reports voting outcomes for two matters: (1) election of three Class II directors (Evert Schimmelpennink, Jeff George, and Shelley Thunen), and (2) ratification of Ernst & Young LLP as independent auditor. The tabulated vote counts for each nominee and proposal are the core content of Item 5.07, which is the standard Item for reporting annual meeting results.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Playtika's annual meeting of stockholders held on June 11, 2026, including voting outcomes for three proposals: election of six directors, ratification of the independent auditor (Kost Forer Gabbay & Kasierer), and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a standard shareholder vote results disclosure that is material to investors' understanding of corporate governance.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Enovix's 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting outcomes for three proposals: election of eight directors, advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. All three proposals were approved by stockholders with detailed vote tallies (For, Against, Abstain, and Broker Non-Votes). This is a material disclosure as it documents shareholder approval of the board composition and executive compensation arrangements.
View raw filing on EDGAR →NEONC Technologies entered into a Securities Purchase Agreement to issue up to $5,000,000 of Series A Convertible Preferred Stock in a private placement to accredited investors under Section 4(a)(2) and Regulation D Rule 506 exemptions. The 6,000 shares of Series A Preferred Stock carry conversion rights into common stock at 80% of the lowest closing price during the five trading days prior to conversion, subject to a beneficial ownership limitation of 4.99% (or 9.99% upon election), resulting in material dilution to existing common shareholders.
View raw filing on EDGAR →The Company issued an unsecured promissory note of $191,475 to its sponsor to fund a trust account extension, creating a direct financial obligation with conditional forgiveness and conversion rights that affects the Company's capital structure and timeline for completing its initial business combination.
View raw filing on EDGAR →The Company issued an unregistered convertible note with underlying Units issuable upon conversion, subject to registration rights and transfer restrictions tied to the initial business combination, representing a dilutive issuance of equity securities.
View raw filing on EDGAR →The Company extended its Business Combination Deadline from June 13, 2026 to July 13, 2026 for its merger with MicroTouch Technology Inc., a governance action that materially affects the transaction timeline and likelihood of consummation.
View raw filing on EDGAR →